6801 related articles for article (PubMed ID: 35072628)
21. Harnessing preexisting influenza virus-specific immunity increases antibody responses against SARS-CoV-2.
Dulin H; Barre RS; Xu D; Neal A; Vizcarra E; Chavez J; Ulu A; Yang M-S; Khan SR; Wuang K; Bhakta N; Chea C; Wilson EH; Martinez-Sobrido L; Hai R
J Virol; 2024 Feb; 98(2):e0157123. PubMed ID: 38206036
[TBL] [Abstract][Full Text] [Related]
22. Characterization of SARS-CoV-2-Specific Humoral and Cellular Immune Responses Induced by Inactivated COVID-19 Vaccines in a Real-World Setting.
Li Z; Xiang T; Liang B; Deng H; Wang H; Feng X; Quan X; Wang X; Li S; Lu S; Yang X; Wang B; Zelinskyy G; Trilling M; Sutter K; Lu M; Dittmer U; Yang D; Zheng X; Liu J
Front Immunol; 2021; 12():802858. PubMed ID: 35003131
[TBL] [Abstract][Full Text] [Related]
23. Antibody affinity maturation and cross-variant activity following SARS-CoV-2 mRNA vaccination: Impact of prior exposure and sex.
Tang J; Grubbs G; Lee Y; Huang C; Ravichandran S; Forgacs D; Golding H; Ross TM; Khurana S
EBioMedicine; 2021 Dec; 74():103748. PubMed ID: 34902788
[TBL] [Abstract][Full Text] [Related]
24. Humoral immune responses during SARS-CoV-2 mRNA vaccine administration in seropositive and seronegative individuals.
Fraley E; LeMaster C; Geanes E; Banerjee D; Khanal S; Grundberg E; Selvarangan R; Bradley T
BMC Med; 2021 Jul; 19(1):169. PubMed ID: 34304742
[TBL] [Abstract][Full Text] [Related]
25. Comparative kinetics of SARS-CoV-2 anti-spike protein RBD IgGs and neutralizing antibodies in convalescent and naïve recipients of the BNT162b2 mRNA vaccine versus COVID-19 patients.
Trougakos IP; Terpos E; Zirou C; Sklirou AD; Apostolakou F; Gumeni S; Charitaki I; Papanagnou ED; Bagratuni T; Liacos CI; Scorilas A; Korompoki E; Papassotiriou I; Kastritis E; Dimopoulos MA
BMC Med; 2021 Aug; 19(1):208. PubMed ID: 34420521
[TBL] [Abstract][Full Text] [Related]
26. Function Is More Reliable than Quantity to Follow Up the Humoral Response to the Receptor-Binding Domain of SARS-CoV-2-Spike Protein after Natural Infection or COVID-19 Vaccination.
Sariol CAA; Pantoja P; Serrano-Collazo C; Rosa-Arocho T; Armina-Rodríguez A; Cruz L; Stone ETT; Arana T; Climent C; Latoni G; Atehortua D; Pabon-Carrero C; Pinto AKK; Brien JDD; Espino AMM
Viruses; 2021 Sep; 13(10):. PubMed ID: 34696403
[TBL] [Abstract][Full Text] [Related]
27. Structure of a Vaccine-Induced, Germline-Encoded Human Antibody Defines a Neutralizing Epitope on the SARS-CoV-2 Spike N-Terminal Domain.
Altomare CG; Adelsberg DC; Carreno JM; Sapse IA; Amanat F; Ellebedy AH; Simon V; Krammer F; Bajic G
mBio; 2022 Jun; 13(3):e0358021. PubMed ID: 35467422
[TBL] [Abstract][Full Text] [Related]
28. The mRNA-1273 Vaccine Induces Cross-Variant Antibody Responses to SARS-CoV-2 With Distinct Profiles in Individuals With or Without Pre-Existing Immunity.
Tejedor Vaquero S; de Campos-Mata L; Ramada JM; Díaz P; Navarro-Barriuso J; Ribas-Llaurado C; Rodrigo Melero N; Carolis C; Cerutti A; Gimeno R; Magri G
Front Immunol; 2021; 12():737083. PubMed ID: 34539673
[TBL] [Abstract][Full Text] [Related]
29. A Glycosylated RBD Protein Induces Enhanced Neutralizing Antibodies against Omicron and Other Variants with Improved Protection against SARS-CoV-2 Infection.
Shi J; Zheng J; Tai W; Verma AK; Zhang X; Geng Q; Wang G; Guan X; Malisheni MM; Odle AE; Zhang W; Li F; Perlman S; Du L
J Virol; 2022 Sep; 96(17):e0011822. PubMed ID: 35972290
[TBL] [Abstract][Full Text] [Related]
30. B and T cell response to SARS-CoV-2 vaccination in health care professionals with and without previous COVID-19.
Zollner A; Watschinger C; Rössler A; Farcet MR; Penner A; Böhm V; Kiechl SJ; Stampfel G; Hintenberger R; Tilg H; Koch R; Antlanger M; Kreil TR; Kimpel J; Moschen AR
EBioMedicine; 2021 Aug; 70():103539. PubMed ID: 34391087
[TBL] [Abstract][Full Text] [Related]
31. An Intranasal OMV-Based Vaccine Induces High Mucosal and Systemic Protecting Immunity Against a SARS-CoV-2 Infection.
van der Ley PA; Zariri A; van Riet E; Oosterhoff D; Kruiswijk CP
Front Immunol; 2021; 12():781280. PubMed ID: 34987509
[TBL] [Abstract][Full Text] [Related]
32. Structural and antigenic variations in the spike protein of emerging SARS-CoV-2 variants.
Mittal A; Khattri A; Verma V
PLoS Pathog; 2022 Feb; 18(2):e1010260. PubMed ID: 35176090
[TBL] [Abstract][Full Text] [Related]
33. Epitopes of an antibody that neutralizes a wide range of SARS-CoV-2 variants in a conserved subdomain 1 of the spike protein.
Ishimaru H; Nishimura M; Shigematsu H; Marini MI; Hasegawa N; Takamiya R; Iwata S; Mori Y
J Virol; 2024 May; 98(5):e0041624. PubMed ID: 38624232
[TBL] [Abstract][Full Text] [Related]
34. SARS-CoV-2 Evolution and Patient Immunological History Shape the Breadth and Potency of Antibody-Mediated Immunity.
Manali M; Bissett LA; Amat JAR; Logan N; Scott S; Hughes EC; Harvey WT; Orton R; Thomson EC; Gunson RN; Viana M; Willett B; Murcia PR
J Infect Dis; 2022 Dec; 227(1):40-49. PubMed ID: 35920058
[TBL] [Abstract][Full Text] [Related]
35. Targeting intra-viral conserved nucleocapsid (N) proteins as novel vaccines against SARS-CoVs.
Thura M; Sng JXE; Ang KH; Li J; Gupta A; Hong JM; Hong CW; Zeng Q
Biosci Rep; 2021 Sep; 41(9):. PubMed ID: 34519332
[TBL] [Abstract][Full Text] [Related]
36. Computational Analysis of Mutations in the Receptor-Binding Domain of SARS-CoV-2 Spike and Their Effects on Antibody Binding.
Bozdaganyan ME; Shaitan KV; Kirpichnikov MP; Sokolova OS; Orekhov PS
Viruses; 2022 Jan; 14(2):. PubMed ID: 35215888
[TBL] [Abstract][Full Text] [Related]
37. Monoclonal antibodies targeting two immunodominant epitopes on the Spike protein neutralize emerging SARS-CoV-2 variants of concern.
Kovacech B; Fialova L; Filipcik P; Skrabana R; Zilkova M; Paulenka-Ivanovova N; Kovac A; Palova D; Rolkova GP; Tomkova K; Csokova NT; Markova K; Skrabanova M; Sinska K; Basheer N; Majerova P; Hanes J; Parrak V; Prcina M; Cehlar O; Cente M; Piestansky J; Fresser M; Novak M; Slavikova M; Borsova K; Cabanova V; Brejova B; Vinař T; Nosek J; Klempa B; Eyer L; Hönig V; Palus M; Ruzek D; Vyhlidalova T; Strakova P; Mrazkova B; Zudova D; Koubkova G; Novosadova V; Prochazka J; Sedlacek R; Zilka N; Kontsekova E
EBioMedicine; 2022 Feb; 76():103818. PubMed ID: 35078012
[TBL] [Abstract][Full Text] [Related]
38. Predicted Epitope Abundance Supports Vaccine-Induced Cytotoxic Protection Against SARS-CoV-2 Variants of Concern.
Martín-Galiano AJ; Díez-Fuertes F; McConnell MJ; López D
Front Immunol; 2021; 12():732693. PubMed ID: 34899692
[TBL] [Abstract][Full Text] [Related]
39. SARS-CoV-2 variants of concern partially escape humoral but not T-cell responses in COVID-19 convalescent donors and vaccinees.
Geers D; Shamier MC; Bogers S; den Hartog G; Gommers L; Nieuwkoop NN; Schmitz KS; Rijsbergen LC; van Osch JAT; Dijkhuizen E; Smits G; Comvalius A; van Mourik D; Caniels TG; van Gils MJ; Sanders RW; Oude Munnink BB; Molenkamp R; de Jager HJ; Haagmans BL; de Swart RL; Koopmans MPG; van Binnendijk RS; de Vries RD; GeurtsvanKessel CH
Sci Immunol; 2021 May; 6(59):. PubMed ID: 34035118
[TBL] [Abstract][Full Text] [Related]
40. Long-Term Humoral Immune Response against SARS-CoV-2 after Natural Infection and Subsequent Vaccination According to WHO International Binding Antibody Units (BAU/mL).
Ruetalo N; Flehmig B; Schindler M; Pridzun L; Haage A; Reichenbächer M; Kirchner T; Kirchner T; Klingel K; Ranke MB; Normann A
Viruses; 2021 Nov; 13(12):. PubMed ID: 34960605
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
